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Immunobiologicals are the biologically active agents with immunological actions that are useful for the management of immunologically mediated 
diseases of infectious or non-infectious origin.
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INTRODUCTION
Biologicals are molecules that modify the cascade of immunological 
processes leading to inflammation. Principal immunobiologicals are 
monoclonal antibodies (Mabs), fusion inhibitors, and interferons 
(IFNs). Paul Ehrlich first described Mab as “magic bullets” in search of 
toxins.
An antibody is a protein used by the immune system to identify and 
neutralize foreign objects such as bacteria and viruses. Each antibody 
recognizes a specific antigen unique to its target.
Mabs are antibodies that are identical because they were produced by 
one type of immune cell, all clones of a single parent cell. Polyclonal 
antibodies are antibodies that are derived from different cell lines. They 
differ in amino acid sequence.
The antigen associated with tumor cells are called as the “TUMOR 
MARKER.” Antibodies produced as a result of specific tumor markers 
monoclonally can be conjugated with drug molecule which, in turn, can 
be targeted to the specific cells or tumor tissues. Targeting antibodies 
with drugs involve the following steps: (1) Identification of the new 
antigen produced by the tumor cells, (2) production of antibody 
monoclonally against the identified new antigen, and (3) formation of 
drug antibody conjugate or complexes.
These complexes concentrate at the tumor site and deliver the drug. 
There are several advantages when drugs are delivered as antibody 
conjugates. The conjugates can specifically reach the target cells 
without causing any damage to the normal tissue. The drug antibody 
conjugate could be expected to be the ideal agents for drug targeting in 
chemotherapy.
Production of Mab
An antigen is injected into a mouse, and after a few weeks, its spleen 
is removed and plasma cells are extracted. The mouse’s spleen cells 
are fused with myeloma cells to create hybrid cells called hybridoma 
cells. Each hybridoma cell indefinitely produces identical antibody, 
and the hybridoma cells are then screened using an antigen/antibody 
assay that will reveal which cells produce the desired antibody. The 
collection of selected hybridoma cells that produce the preferred 
antibody is rescreened multiple times until a pure line is isolated. 
These cells are grown in a culture and/or injected into mice to 
induce tumors. The cells can also be frozen and saved for later use. 
The hybridoma method for producing Mab is useful because large 
amounts of specifically tailored identical antibodies can be produced 
easily [1].
PRODUCTION OF MAB
Mabs are classified according to the decreased order of antigenicity of 
their components intomurine, chimeric, primatized, and humanized.
TYPES OF MAB
1. Murine Mab: Whole antibody is of murine origin produced by 
hybridoma technology. Major problems with murine Mabs include 
reduced stimulation of cytotoxicity, formation of complexes after 
repeated administration, allergic reactions, and anaphylactic shock, 
for example, Afelimomab.
2. Chimeric Mab: Chimeric antibodies composed of murine variable 
regions fused onto human constant regions developed by 
recombinant DNA technology. Antibodies are approximately 65% 
human origin. This reduces immunogenicity, thus increases serum 
half-life, for example, Basiliximab and Cetuximab.
3. Humanized Mab: Humanized antibodies are produced by grafting 
murine hypervariable domains into human antibodies are 
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approximately 90–95% human origin this bind weakly to the 
antigens, for example, Apolizumab and Atlizumab.
4. Human Mab: Human Mabs are produced by transferring human 
immunoglobulin genes into the murine genome, after which the 
transgenic mouse is vaccinated against the desired antigen, leading 
to the production of Mab, for example, Belimumab and Cixutumumab.
Mechanism of action of Mab
Antibody-dependent cell-mediated cytotoxicity (ADCC)
ADCC immunoglobulin’s clustered on the surface of the targeted cells 
and exposes its tail (Fc) region to be recognized by the Fc receptors 
present on the surface of the macrophages and neutrophils. This causes 
lysis of tumor cell.
Radioimmunotherapy
It involves the use of radioactively conjugated murine antibodies 
against cellular antigens. Emitted radiation causes tumor cell lysis. More 
applicable to lymphomas as they are highly radiosensitive malignancies.
Antibody-mediated enzyme prodrug therapy
An antibody developed against a tumor antigen is linked to a drug-
activating enzyme and injected to the blood subsequent systemic 
administration of non-toxic agent or prodrug results in its conversion 
to a toxic drug and results in cytotoxic effect.
Immunoliposomes
These are antibody conjugated liposome’s can carry drugs or 
therapeutic nucleotides and when conjugated with Mab, deliver the 
entrapped drug or toxin, especially to the target cells.
Immunotoxins
Immunotoxins are proteins that contain a toxin along with an antibody 
that binds specifically to target cells. All protein toxins are work by 
enzymatically inhibiting protein synthesis. Various plant and biological 
toxins have been genetically fused/chemically conjugated with the 
antibodies that bind to cancer cells.
Antibody drug conjugates
Antibody-drug conjugates are Mab attached to biologically active drugs 
by chemical linkers with liable bonds reduce side effects and show wide 
therapeutic window doxorubicin, duanomycin, chlorambucil, etc., can 
be conjugated with Mab.
Fragments of Mabs
Cytokine blocking agents Target Type Indication
Afelimomab Anti-TNF-α Protein Sepsis
Infliximab (Remicade) Anti-TNF-α Chimeric Behcet’s disease Toxic epidermal 
necrolysis
Etanercept (Enbrel) Anti-TNF-α and TNF-ß Fusion protein Pemphigus
Agents targeting cell surface epitopes
Alefacept (Amevive) CD-2-LFA-3 Fusion protein Psoriasis
Alemtuzumab (Campath) CD-52 Humanized Chronic lymphocytic leukemia
Apolizumab HLA-DR beta Humanized Non-Hodgkin’s lymphoma
Belimumab (Benlysta) B-cell-activating factor (BAFF) Humanized Sjogren’s syndrome Systemic lupus 
erythematosus (SLE)
Bevacizumab (Avastin) Vascular endothelial growth factor (VEGF) Humanized Colorectal cancer
Basiliximab (Simulect) CD-25 Humanized Mab Transplant rejection
Cetuximab (Erbitux) Epidermal growth factor receptor (EGFR) Chimeric Head and neck cancer
Certolizumab (Cimzia) Inhibition of TNF-α signaling Humanized Crohn’s disease
Cixutumumab IGF-1 receptor Human Metastatic Rhabdomyosarcoma 
Hepatocellular carcinoma
Daclizumab (Zenapax) CD-25 Humanized Mab Transplant rejection
Denileukin Diftitox (Ontak) CD25/Ib 2 Fusion toxin Cutaneous T-cell lymphoma
Efalizumab (Raptiva) CD-11 a/CD18 Humanized Mab Psoriasis
Eculizumab (Soliris) Complement system protein C5 Humanized Paroxysmal nocturnal hemoglobinuria
Gemtuzumab (Mylotarg) CD-33 Humanized Acute myelogenous leukemia
Ibritumomab (Zevalin) CD-20 Murine Non-Hodgkin’s lymphoma (with 
Yttrium-90 or Indium-111)
Mepolizumab (Nucala) IL-5 α of Eosinophil Humanized Asthma
Siplizumab CD-2 Humanized Mab Graft versus host disease psoriasis
Tocilizumab (Actemra) IL-6 Humanized Rheumatoid arthritis
Visilizumab (Nuvion) CD-3 Humanized Cohn’s disease ulcerative colitis
Mabs: Monoclonal antibodies, IL: Interleukin, TNF: Tumor necrosis factor
Mab Dosages
Infliximab (REMICADE) 5 mg/kg/dose i.v alone or in combination with other agents 100 mg injection
Etanercept (ENBREL) 25 mg subcutaneously. Twice weekly for minimum 12 weeks
Alefacept (AMEVIVE) 10–15 mg intramuscular injection once weekly for 12 weeks
Efalizumab (RAPTIVA) 0.7 mg/kg subcutaneous injection (conditioning dose) followed by weekly subcutaneous doses of 1 mg/
kg (maximum single dose not to exceed a total of 200 mg). A single vial delivers 125 mg
Denileukin Diftitox (ONTAK) 9–18 mcg/kg/d intravenous infusion daily for 5 days every 3 weeks, six courses are required to show partial or 
complete response. A single vial delivers 150 mcg/ml per vial
Mabs: Monoclonal antibodies
Fragments of Mabs Fab and F(ab) 2 are less immunogenic but have 
greater tumor penetration power than normal antibody and are helpful 
in detecting smaller lesions (<2 cm) not seen on computed tomography. 
ScFv is mainly used as delivery vehicles for cancer therapy.
Table 1: Immunobiologicals [2]
Table 2: Dosages of some Mab
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may lead to the damage of normal cells.
5. Tumor uptake may be increased through administering high doses.
Disadvantages of Mab 
1. Mab production, a time-consuming process because entire process 
requires 3–4 months for one fusion experiment.
2.	 Average	affinity	of	Mab	is	generally	lower.
3. Any physical/chemical treatment will affect all Mabs in that production.
IFN
IFNs are a family of glycoproteins which are synthesized by leukocytes 
(IFN-α),	 fibroblasts	 (IFN-β),	 and	 immune	 cells	 (IFN-ɤ)	 against	 viral	
infections and other non-viral challenges that in addition to having 
antiviral	properties,	also	modulate	various	cellular	functions.	IFN-α	is	
mainly used for therapeutic purposes.
IFN synthesized by recombinant techniques have therapeutic value in 
the treatment of viral infections of the skin and cutaneous malignancies. 
They are the products of bacterial fermentation of particular strain of 
Escherichia coli consisting genetically engineered plasmid containing a 
specific IFN gene from human leukocytes.
Mechanism of action of IFN
Antiviral
It induces enzyme 2՜-5′	a synthetase, polymerizes ATP, activates cellular 
endonuclease, and degrade both viral and cellular RNA.
Antiproliferative effect
It inhibits mitosis of the cells and downregulates their growth factors.
Immunoregulatory effect
It induces expression of Classes I and II MHC complexes antigens on 
immune cells, enhances number of natural killer cells.
Principle indications of IFN
IFN-α2A
Recurrent aphthous stomatitis
IFN-α2A	 administered	 orally	 once	 daily	 in	 a	 low	 concentration	
(1200 IU/day) for 1 week [3].
Hemangioma
IFN-α2A	 3	 million	 units/m2 per day should be used only in life-
threatening hemangiomas act by inhibiting angiogenesis in whom high-
dose corticosteroid therapy failed [4].
Chronic hepatitis B infection
About 10 MU/L pegylated IFN-alpha is used in the treatment of chronic 
hepatitis B infection [5].
Malignant melanoma
About 20 MU/m2 i.v over 20 min for 5 consecutive days/week 
for 4 weeks (induction phase) followed by 10 MU/m2 s.c injection 
3	 times/week	 for	 48	 weeks	 (maintenance	 phase).	 IFN-α2b	 has	
a dual effect of TAP1 (antigen-presenting cells of MHC complex) 




Used for the treatment of recalcitrant moderate-to-severe atopic 
dermatitis acts by inhibiting IgE synthesis by promoting proliferation 
of Th1 cells administered by weekly subcutaneous injections [8].
Intravenous immunoglobulins
Intravenous immunoglobulins are heterogeneous human gamma 
globulins consisting IgG with trace of IgA and IgM prepared by cold 
ethanol fractionalization of pooled human sera harvested from 
thousands of donors. Intravenous immunoglobulins are an important 
safe, effective therapeutic option as an immunomodulatory agent 
in the management of skin disorders where corticosteroids and 
immunosuppressive agents cannot be used.
Mechanism of action of intravenous immunoglobulins
1. Neutralization of microbe or toxin.
2. Inhibition of cytokines such as interleukin (IL)-1, IL-6, and tumor 
necrosis	factor-α.
3. Superantigen neutralization.
4. Modulation of complement activation.
5. Acceleration of IgG catabolism.
6. Saturation of Fc receptors on macrophages (Fc receptors play a role 
in cytotoxic cell-mediated immunity and opsonization).
7. Suppression of antibody production and idiotypic (the variable part 
of an antibody including the unique antigen-binding site is known 
as idiotype) antibodies.
8. Helps to clear immune complexes from the body in patients affected 
with systemic lupus erythematosus.
Indication Doses and duration
Pemphigus vulgaris 2 g/kg i.v. single dose monthly or 1 g/kg/day×3 days every month or 
0.5 g/kg/day×5 days every month
Toxic epidermal necrolysis 0.8–5.8 g/kg for 1–5 days
Dermatomyositis 2 g/kg i.v single dose monthly for 2–4 months
Graft versus host disease (GVHD) 250–500 mg/kg weekly from day 8 to day 111 after bone marrow 
transplantation
Autoimmune urticaria 0.4/kg/day for 5 days
Kawasaki disease 2 g/kg i.v as single dose
Congenital/acquired agammaglobulinemia or hypogammaglobulinemia 0.25 g/kg every 3 weeks in childhood
Scleromyxedema 2 g/kg i.v. monthly for 3 months
Pyoderma gangrenosum 1–2 g/kg i.v. monthly for 2–4 months
Table 3: Indications and doses of intravenous immunoglobulins
Problems of drug delivery by Mab [12]
1. Slow elimination of Mab from the blood.
2. Poor vascular permeability.
3. Cross-reactivity with normal tissues, metabolism of Mab conjugates.
4. May bind with the targeted epitopes present on other tissues, which 
1 MU per lesion (maximum of 5 lesions in a single course). Intralesional 
injections should be 3 times weekly on alternate days for 3 
weeks directed toward the center of the base of the lesion, which 
produce a small wheal if done correctly. An additional course may be 
administered at 12–16 weeks [7].
AIDS-related Kaposi’s sarcoma
30 MU/m2/dose subcutaneously or intramuscularly 3 times a week for
 16 weeks of treatment till maximum response.
5% lyophilized powder dissolved in 5% dextrose. Available as immuglob 
2.5 g/100 ml or 5 g/200 ml Vial. Since it is not compatible with normal
 saline, it has to be diluted with 5% dextrose in water. 18
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Disadvantages of intravenous immunoglobulins
1. All intravenous immunoglobulins must be screened to minimize the 
risk of transmission of HIV, hepatitis B virus, and hepatitis C virus 
infection.
2. Can interact with live virus vaccines. Such vaccines should not be 
given 14 days before or 3 months after intravenous immunoglobulin 
administration.
3. Have risk of autoimmunity owing to infusion of antibodies.
4.	 Rebound	 flare-up	can	occur	after	discontinuation	of	 intravenous	
immunoglobulins.
5. Anaphylactic reactions can occur.
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